SARS-CoV-2 inhibits the cellular response to interferon

Severe coronavirus disease 2019 (COVID-19) is associated with the development of acute respiratory distress syndrome (ARDS), characterized by exacerbated inflammation in the lungs and significantly upregulated production of cytokines. The increased expression of genes associated with interferon production is often observed in those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, though serum levels are frequently unexpectedly low. Intranasal, though not intravenous, administration of type I interferon has also been shown to be beneficial to mice infected with SARS-CoV-2, suggesting that the way in which the cells of the airway and alveolar detect and respond to the virus by producing interferon may have been negatively impacted following infection.

Study: The RNA sensor MDA5 detects SARS-CoV-2 infection. Image Credit: NIAID / Flickr
Study: The RNA sensor MDA5 detects SARS-CoV-2 infection. Image Credit: NIAID / Flickr

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

The early cellular response to viral challenge is largely mediated by proteins that detect foreign nucleic acid sequences in the cytosol. Retinoic acid-inducible gene-I-like receptors are a family of pattern recognition receptor proteins that have been implicated in the sensing of coronaviruses. Two proteins within this family that detect specific types of RNA structure are: retinoic acid-inducible 60 gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5). Once bound with viral RNA, these proteins trigger a signaling cascade that results in the production of cytokines such as interferon. In a paper recently uploaded to the preprint server bioRxiv*, researchers explored the effect of SARS-CoV-2 infection on the function of RIG-I and MDA5, and ultimately on interferon production.

The role of pattern recognition receptors in SARS-CoV-2 sensing

The group screened several cell lines for their ability to host SARS-CoV-2 and detectably produce virus nucleocapsid RNA within 24 hours, finding that Calu-3, HEK293, and Huh7 cells, could host the virus, but only Calu-3 cells induced a detectable cytokine response. Calu-3 cells are sourced from human lung tissue and may therefore be better evolved to provide an immune response against coronaviruses. Upregulation of type I and III interferons was observed upon infection, alongside other proinflammatory cytokines such as interleukin-6, and the major immune signaling pathways were activated, including RIG-I and MDA5.

Short hairpin RNA (shRNA) is a synthetic molecule used to silence gene expression by RNA interference. shRNA was used to knockdown mitochondrial antiviral-signaling protein (MAVS), with which both RIG-I and MDA5 must interact following binding with viral RNA. Knockdown cells experienced a higher load of SARS-CoV-2 and exhibited depleted interferon levels, though the levels of mRNA coding for some other cytokines (interleukin-6 and tumor necrosis factor) were not altered.

Cells with knocked out MDA5 or interferon regulatory factor 3 (IRF3), which is activated downstream of MAVS, showed the lowest concentration of interferon coding mRNAs in response to SARS-CoV-2 infection, while also maintaining IL-6 and TNF levels. Knocking out RIG-I or stimulator of interferon genes (STING), a cystolic DNA sensor, had little influence on SARS-CoV-2 infection, suggesting that the cystolic GMP-AMP synthase-STING pathway is not involved in SARS-CoV-2 sensing.

Interferon suppression by SARS-CoV-2

The group demonstrated that the RNA sensor MDA5 and its downstream partners MAVS and IRF3 are involved in the type I and III interferon response to SARS-CoV-2, while RIG-I is largely uninvolved, as has been supported by several other studies. However, the authors highlight several reports of opposing results, which include indications that RIG-I is involved in sensing additionally or in lieu of MDA5. A diverse range of other pattern recognition receptors are involved in the immune response, and the reason for the observed variation is not yet entirely understood. The STING system, for example, has been shown to be activated following cell damage by other infections such as Dengue virus. Though the response to coronavirus is not yet known, it could become active at time points later than observed in this study.

Importantly, the group noticed that infected cells demonstrated lowered MxA protein production compared with uninfected bystanders, a virus inhibitor expressed in response to interferon, IL-6, and other cytokines. This suggests that SARS-CoV-2 suppresses an upstream elicitor of this protein, indicated to be interferon, by encoding a viral protein that interferes with the system, as has been suggested by this and other work. Open reading frame 3a of SARS-Cov-1 is known to target and inhibit the interferon alpha/beta receptor, a widespread membrane receptor of type I interferon, and the group suggests that SARS-CoV-2 likely produces additional proteins that block interferon signaling.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • Apr 7 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Michael Greenwood

Written by

Michael Greenwood

Michael graduated from the University of Salford with a Ph.D. in Biochemistry in 2023, and has keen research interests towards nanotechnology and its application to biological systems. Michael has written on a wide range of science communication and news topics within the life sciences and related fields since 2019, and engages extensively with current developments in journal publications.  

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Greenwood, Michael. (2023, April 07). SARS-CoV-2 inhibits the cellular response to interferon. News-Medical. Retrieved on November 22, 2024 from https://www.news-medical.net/news/20210331/SARS-CoV-2-inhibits-the-cellular-response-to-interferon.aspx.

  • MLA

    Greenwood, Michael. "SARS-CoV-2 inhibits the cellular response to interferon". News-Medical. 22 November 2024. <https://www.news-medical.net/news/20210331/SARS-CoV-2-inhibits-the-cellular-response-to-interferon.aspx>.

  • Chicago

    Greenwood, Michael. "SARS-CoV-2 inhibits the cellular response to interferon". News-Medical. https://www.news-medical.net/news/20210331/SARS-CoV-2-inhibits-the-cellular-response-to-interferon.aspx. (accessed November 22, 2024).

  • Harvard

    Greenwood, Michael. 2023. SARS-CoV-2 inhibits the cellular response to interferon. News-Medical, viewed 22 November 2024, https://www.news-medical.net/news/20210331/SARS-CoV-2-inhibits-the-cellular-response-to-interferon.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Public trust in COVID-19 vaccine science influences vaccine uptake in the US